CRMD vs GYRE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CRMD · CorMedix$5.27 ▲ 3.74%
GYRE · Gyre Therapeutics$4.21 ▼ 6.86%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CRMD -46.3%
- GYRE -46.5%
Head to head
| Metric | CRMD | GYRE |
|---|---|---|
| Price | $5.27 | $4.21 |
| Change today | ▲ 3.74% | ▼ 6.86% |
| Market cap | $419.16M | $460.79M |
| Return, 3 months | -36.4% | -34.6% |
| Return, year to date | -54.7% | -40.4% |
| Return, 1 year | -45.6% | -44.2% |
| P/E (TTM) | 8.2 | – |
| P/B | 0.9 | 4.3 |
| P/E percentile vs own 5y | 89th | 10th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -50.8% | +0.7% |
| Net profit growth (YoY) | -113.6% | -228.6% |
| Gross margin | 77.0% | 93.5% |
| Operating margin | 39.4% | -16.6% |
| Net margin | 15.6% | -22.7% |
| Return on equity | 15.1% | -23.8% |
| Analyst target vs. price | +165.7% | +327.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 40 | 37 |
| 30-day volatility | 108.1% | 133.1% |
| Max drawdown, 1 year | -64.7% | -54.2% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GYRE is the largest of the group by market value.
- GYRE has returned the most over the past year.
- GYRE is growing revenue fastest.
- CRMD keeps the most profit per dollar of sales.
- CRMD has been the calmest stock over the last 30 days.